Nektar Therapeutics

We figured that out in our atopic dermatitis program, the ideal maintenance dosing after a 16 or 24 week induction period should be one month and three months. In terms of alopecia areata, after 52 weeks of treatment, we don't yet know what the maintenance dosing should be. And so for that off treatment, data that we're going to have at the end of this year, it's going to be highly informative to us to understand how we should continue to dose patients in the alopecia areata program after 52 weeks of treatment given 24 micrograms per kilogram every two weeks. In terms of the data from the RESOLVE-AD study, you're absolutely right. We'll continue to follow the durability of those patients' responses and those patients who achieved an EZ75, an EZ90, an IgA0 and 1, and we'll continue to look at the durability of those responses. As we saw with Q monthly dosing and Q three-month dosing, we had exceptional durability, and we also saw deepening of responses. Now, with the off-treatment, we'll be able to determine, you know, are patients able to maintain those easy 100 responses, the 30% of patients that achieved that, and the IgA zero and one responses. And remember, we had roughly 60% of patients who had an easy 75 or VIGA at the time of re-randomization achieving an IgA of zero and one. So we'll be very eager to see the durability of maintaining the EZ75, the EZ100, and the VIGA01. I think this will be highly informative, again, to understand the dosing frequency for these patients after they're treated with 52 weeks of treatment. So you're absolutely right. The standard endpoints that we use for clinical trials will also be the endpoints that we'll look at in the off-treatment timeframe. Thanks for the question.

Thank you. Our next question comes from Mark Fromm from TD Cowan. Your line is open.

Thanks for taking my questions and congrats on all the progress getting the trials designed. Maybe just on that bio experience. patient study in atopic dermatitis. Can you just walk through kind of how you're defining bioexperience there? You know, will patients be required to have, you know, overtly failed therapy, or could they have discontinued for any other reason? Just, you know, how long do they have to have been off therapy, things like that. And will that include JAK experience patients or just focused on the IL-413 pathway?